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MemoryAcetylcholinesterase (AChE) is distributed throughout the body in both neuronal and non-neuronal tissues and
plays an important role in the regulation of physiological events. Caffeic acid is a phenolic compound that has
anti-inﬂammatory and neuroprotective properties. The aim of this study was to investigate in vitro and in vivo
whether caffeic acid alters the AChE activity and behavioral parameters in rats. In the in vitro study, the concen-
trations of 0, 0.1, 0.5, 1.0, 1.5, and 2 mM of caffeic acid were used. For the in vivo study, ﬁve groups were
evaluated: group I (control); group II (canola oil), group III (10 mg/kg of caffeic acid); group IV (50 mg/kg of
caffeic acid) and group V (100 mg/kg of caffeic acid). Caffeic acid was diluted in canola oil and administered
for 30 days. In vitro, the caffeic acid increased theAChE activity in the cerebral cortex, cerebellum, hypothalamus,
whole blood, and lymphocytes at different concentrations. In muscle, this compound caused an inhibition in the
AChE activity at concentrations of 0.5, 1.0, 1.5, and 2 mMwhen compared to the control (Pb0.05). In vivo, 50 and
100 mg/kg of caffeic acid decreased the AChE activity in the cerebral cortex and striatum and increased the
activity of this enzyme in the cerebellum, hippocampus, hypothalamus, pons, lymphocytes, and muscles when
compared to the control group (Pb0.05). The amount of 100 mg/kg of caffeic acid improved the step-down
latencies in the inhibitory avoidance. Our results demonstrated that caffeic acid improved memory and inter-
fered with the cholinergic signaling. As a natural and promising compound caffeic acid should be considered
potentially therapeutic in disorders that involve the cholinergic system.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Cholinesterases belong to a family of proteins that is widely distribut-
ed throughout the body in both neuronal and non-neuronal tissues and is
classiﬁed as either acetylcholinesterase (AChE) or butyrylcholinesterase
(BuChE) based on their substrate and inhibitor speciﬁcity (Anglister et
al., 2008).
Acetylcholinesterase (E.C. 3.1.1.7, AChE) is a speciﬁc choline esterase
that hydrolyzes predominantly choline esters. This enzyme is present in
the brain, erythrocytes, lymphocytes and neuromuscular junction andós-Graduação em Bioquímica e
s e de Alimentos, Universidade
96010-900 Pelotas, RS, Brazil.
de Química, Centro de Ciências
Campus Universitário, Camobi,
8.
nevello),
vier OA license.plays an essential role in the regulation of physiological events involv-
ing the turnover of acetylcholine (Anglister et al., 2008; Szelenki et al.,
1982; Gaspersic et al., 1999). AChE is one of the most efﬁcient enzymes
that rapidly hydrolyzes the neurotransmitter acetylcholine at choliner-
gic synapses as well as the neuromuscular junction (Anglister et al.,
2008; Gaspersic et al., 1999). Besides its catalytic properties, AChE has
potent effects in cellular adhesion, neurite extension and postsynaptic
differentiation and has been accepted as the most important biochemi-
cal indicator of cholinergic signaling in the central nervous system
(CNS) (Silman and Sussman, 2005). This enzyme is also widely accept-
ed as having roles in non-neuronal tissues including hematopoietic dif-
ferentiation (Deutsch et al., 2002) and regulation of the immune
function (Kawashima and Fujii, 2003).
As a consequence of its key physiological role, AChE is the target of
natural toxins (Senanayake and Román, 1992) and the therapeutic
drugs designed to combat neuromuscular disorders and to alleviate
the cholinergic deﬁciency associated with neurodegenerative diseases
(Brenner et al., 2003). Furthermore, several studies have also demon-
strated that natural substances and dietary components can affect the
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al., 2009).
Caffeic acid (3,4-dihydroxycinnamic acid) is a non-ﬂavanoid
catecholic compound present in many plants and occurs in the diet
as part of fruits, tea and wine (Clifford, 1999). Even though caffeic acid
is a phenolic compound especially abundant in coffee, it is chemically
unrelated to caffeine (Higdon and Frei, 2006; Omar et al., 2012). It is
known that caffeic acid has a broad spectrum of pharmacological activ-
ities including anti-inﬂammatory, antioxidant and immunomodulatory
effects (Challis and Bartlett, 1995; Chan and Ho, 1997; Gulcin, 2006).
Pharmacology studies have also shown that the caffeic acid exerts a pro-
tective effect against hydrogen peroxide-induced oxidative damage in
the brain (Pereira et al., 2006), and cerebral ischemia (Zhou et al.,
2006) and prevents brain damage aswell as behavioral and biochemical
changes caused by aluminum (Yang and Zho, 2008). Although many of
these effects have been partially related to 5-lipoxigenase inhibition,
the mechanisms involved in the protective activities of caffeic acid
have not yet been fully understood. In addition, there are few studies
about the effects promoted by caffeic acid on cholinergic signaling pa-
rameters in CNS as well in other tissues.
Lately, the effects of compounds present in the diet as an alterna-
tive source for the treatment of various diseases have been studied. In
this context, considering the pharmacological properties of caffeic
acid, the aim of this study was to investigate the effects of this com-
pound on behavioral parameters as well as on the activity of the
AChE enzyme in the brain, lymphocytes, whole blood and muscle of
rats in order to investigate the potentially therapeutic use of this
compound in disorders associated with cholinergic dysfunction.
2. Material and methods
2.1. Chemicals
Caffeic acid, acetylthiocholine iodide (ASCh), 5,5′-dithio-bis-2-
nitrobenzoic acid (DTNB) and Triton X-100 were obtained from Sigma
(Deisenhofen, Germany), while ethopropazine hydrochloride was
obtained from Aldrich (Steinheim, Germany). Ficoll Hypaque
(Lymphoprep™) was purchased from Nycomed Pharma (Oslo,
Norway). All the other reagents used in the experiments were of
analytical grade and of the highest purity.
2.2. Animals
Male Wistar rats (70 days, 280–300 g) from the Central Animal
House of the University Federal of Santa Maria (UFSM) were used.
Animals were maintained at a constant temperature (23±1 °C) on
a 12 h light/dark cycle with free access to food andwater. The animals
were used according to the guidelines of the Committee on Care and
Use of Experimental Animal Resources, (COBEA) which are in accor-
dance with international guidelines. After the acclimatization period,
the rats were submitted to the experimental protocols.
2.3. In vitro experiments with caffeic acid
Ten adult male Wistar rats were used for the in vitro experiments.
After the acclimatization period, animals were submitted to euthana-
sia after being previously anesthetized with halothane and the brain
structures, blood and muscle were removed. The caffeic acid was
dissolved in the methanol and the different concentrations (0, 0.1,
0.5, 1.0, 1.5 and 2 mM) were used in the assay of the AChE activity.
2.4. In vivo experiments with caffeic acid
Animals were divided into ﬁve groups (10 rats per group): group I
(control); group II (canola oil), group III (treated with 10 mg/kg of
caffeic acid); group IV (treated with 50 mg/kg of caffeic acid) andgroup V (treated with 100 mg/kg of caffeic acid). Caffeic acid was
freshly prepared in canola oil and was administered by gavage once
a day for 30 days. One day after the end of the treatment with caffeic
acid, animals were subjected to behavioral tests. After this procedure,
animals were submitted to euthanasia after being previously anesthe-
tized with halothane and the brain, blood and muscle were removed
for the AChE assay.
2.5. Behavioral procedure
2.5.1. Inhibitory avoidance
For the evaluation ofmemorywe used the inhibitory avoidance task,
which is commonly used to assess memory in rats and mice and it is
considered a very simple test. Training was done only once and had
an important biological value (Izquierdo et al., 2000a,b, 2002). One
day after the end of the treatment, animals were subjected to training
and tested in a step-down inhibitory avoidance apparatus according
to Guerra et al. (2006). Animals were trained in a one-trial step-down
inhibitory avoidance paradigm. The inhibitory avoidance apparatus
consisted of a 30×25×25-cm box with a 2.5-cm high, 7-cm wide, and
25-cm-long platform covering the left side of the grid ﬂoor. During
training, animals were gently placed on the platform facing the left
rear corner of the training box. Immediately after stepping down with
their four paws on the grid, they received a 4-s 0.4 mA scrambled foot
shock. Immediately after training, they were returned to their home
cage. Memory retention was evaluated in a test session carried out
24 h after training, inwhich trained animalswere placed on the training
box platform, and the step-down latency (s) was measured. A cutoff
time of 300 swas imposed on step-down latency during testing session.
The apparatuswas cleanedwith 30% ethyl alcohol before and after each
rat occupied it.
2.5.2. Open ﬁeld
Immediately after the inhibitory avoidance test session, all animals
were transferred to an open ﬁeld in order to assess exploratory activity.
Animals were placed on the center quadrant of a round open ﬁeld
(56 cm diameter) with the ﬂoor divided into ten equal areas. An ob-
server, whowas not aware of the pharmacological treatments, manual-
ly recorded the number of crossing and rearing responses over 5 min.
Crossing was deﬁned as the total number of areas crossed with the
four paws and rearing was deﬁned as the total number of stand up re-
sponses on two paws. This test was carried out to identify possible
motor disabilities that might have inﬂuenced inhibitory avoidance per-
formance at testing.
2.6. AChE assay in brain structures
In both in vitro and in vivo experiments, the brain was separated
into the striatum (ST), hippocampus (HP), cerebral cortex (CC), cerebel-
lum (CB), hypothalamus (HY) and pons (PN) and placed in a solution of
10 mMTris–HCl, pH 7.4, on ice. Brain structureswere homogenized in a
glass potter in Tris–HCl solution. Aliquots of resulting brain structure
homogenates were stored at −30 °C until utilization. Protein varied
for each structure: ST (0.4 mg/ml), HP (0.8 mg/ml), CC (0.7 mg/ml),
CB (0.6 mg/ml) PN (0.7 mg/ml) and HY (0.6 mg/ml); these concentra-
tions were determined by the Coomassie blue method according to
Bradford (1976) using bovine serum albumin as standard solution.
The AChE enzymatic assay was determined by a modiﬁcation of the
spectrophotometric method of Ellman et al. (1961) as previously de-
scribed by Rocha et al. (1993). The reactionmixture (2 mlﬁnal volume)
was composed of 50 mM K+-phosphate buffer, pH 7.5 and 1 mM of
DTNB. The method is based on the formation of the yellow anion,
4,4-dithio-bis-acid-nitrobenzoic measured by absorbance at 412 nm
during 2 min of incubation at 25 °C. The reaction was initiated by
adding 0.8 mM acetylcholine iodide. All samples were run in duplicate
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ASCh/h/mg of protein.2.7. AChE assay in whole blood
Whole blood AChE activitywas determined by themethod of Ellman
et al. (1961)modiﬁed byWorek et al. (1999). The bloodwas collected in
vaccutainer tubes using EDTA as anticoagulant. Samples were hemo-
lyzedwith phosphate buffer, pH 7.4 containing Triton X-100 and stored
at−30 °C for 1 week. The speciﬁc activity ofwhole blood AChEwas cal-
culated from the quotient between the AChE activity and hemoglobin
content and the results are expressed as mU/μmol Hb.2.8. AChE assay in lymphocytes
The blood was collected in vaccutainer tubes using EDTA as antico-
agulant. The peripheral lymphocyteswere isolatedusing Ficoll Hypaque
density gradient as described by Böyum (1968). Lymphocyte viability
and integrity were conﬁrmed by determining the percentage of cells,
excluding 0.1% trypan blue and measuring lactate dehydrogenase
(LDH) activity (Bergmeyer, 1983).
After the isolation of the lymphocytes, the AChE activity was de-
termined according to the method described by Ellman et al. (1961)
modiﬁed by Fitzgerald and Costa (1993). Brieﬂy, proteins of all sam-
ples were adjusted to 0.1–0.2 mg/ml. The amount of 0.2 ml of intact
cells was added to a solution containing 1.0 mM acetylthiocholine,
0.1 mM of DTNB, and 0.1 M phosphate buffer (pH 8.0). Immediately
before and after incubation for 30 min at 27 °C, the absorbance was
read on a spectrophotometer at 412 nm. AChE was calculated from
the quotient between lymphocyte AChE activity and protein content
and the results are expressed as μmol/h/mg of protein.2.9. AChE assay in muscle
The gastrocnemius muscles was homogenized in a glass potter in
Tris–HCl (pH 7.2) solution and centrifuged for 1000 g for 15 min. Al-
iquots of the resulting centrifugation were used to determine the
AChE activity. The AChE enzymatic assay in muscle was determined
by a modiﬁcation of the spectrophotometric method of Ellman et al.
(1961). The reaction mixture (2 ml ﬁnal volume) was composed of
24 mM K+-phosphate buffer, pH 7.2 and 10 mM of DTNB. The reac-
tion was initiated by adding 0.8 mM acetylcholine iodide. All samples
were run in duplicate or triplicate and enzyme activity was expressed
in micromoles ASCh/h/mg of protein.2.10. Protein determination
Protein was measured by the method of Bradford (1976) using bo-
vine serum albumin as standard.2.11. Statistical analysis
Because the distributions of data of inhibitory avoidance test la-
tencies were not normally distributed, the statistical analysis of test
step-down latencies was carried out by Kruskal–Wallis followed by
post hoc analyses (nonparametric Dunn's test) and the results were
expressed as the median and interquartile range. Crossing, rearing,
latency to training and biochemical analysis were normally distribut-
ed and were analyzed by one-way ANOVA followed by post hoc
Duncan's multiple range tests and the results were expressed as
mean±SEM. Pb0.05 was considered to represent a signiﬁcant differ-
ence between groups.3. Results
3.1. In vitro experiments with caffeic acid
Results demonstrated that in vitro caffeic acid altered the AChE ac-
tivity in different brain structures. It can be observed in Fig. 1 that caffeic
acid signiﬁcantly increased the AChE activity in the cerebral cortex at
concentrations of 1.0 mM (18%), 1.5 mM (27%), and 2.0 mM (37%); in
the cerebellum at concentrations of 1.5 mM (20%) and 2.0 mM (22%);
and in the hypothalamus at concentrations of 1.5 mM (42%) and
2.0 mM (42%) when compared to the control group (Pb0.05). In the
striatum, hippocampus and pons caffeic acid did not affect in vitro the
AChE activity at any concentration evaluated.
Fig. 2 shows the effects of caffeic acid on the AChE activity in
whole blood. It can be observed that caffeic acid signiﬁcantly in-
creased the AChE activity in whole blood only at a high concentration
(2 mM (−32%)); whereas in the lymphocytes, caffeic acid signiﬁcantly
increased the enzyme activity at concentrations of 0.5 mM (26%),
1.0 mM (56%), 1.5 mM (68%), and 2.0 mM (68%) when compared with
the control group (Pb0.05) (Fig. 3). On the other hand, this compound
in vitro caused a signiﬁcant inhibition in the AChE activity in muscle at
concentrations of 0.5 mM (28%), 1.0 mM (33%), 1.5 mM (37%), and
2.0 mM (42%) when compared to the control group (Pb0.05) (Fig. 4).
3.2. In vivo experiments with caffeic acid
3.2.1. AChE activity
When rats were treated with caffeic acid, the AChE activity was al-
tered in different brain structures. Fig. 5 shows that in the cerebral cor-
tex ,the AChE activity was signiﬁcantly decreased in the groups treated
with 10 mg/kg (23%), 50 mg/kg (25%) and 100 mg/kg (28%) of caffeic
acid when compared to the control group (Pb0.05). Similarly, in the
striatum the AChE activity was also signiﬁcantly inhibited in the groups
treated with 10 mg/kg (36%), 50 mg/kg (36%), and 100 mg/kg (37%) of
caffeic acid in relation to the control group (Pb0.05). On the other hand,
in the hippocampus the AChE activity was signiﬁcantly increased in the
animals treated with 10 mg/kg (29%), 50 mg/kg (40%) and 100 mg/kg
(40%) of caffeic acid as well as in the pons at dosages of 10 mg/kg
(22%), 50 mg/kg (24%), and 100 mg/kg (22%) of caffeic acid in compar-
ison with the control group (Pb0.05) (Fig. 5). In addition, a signiﬁcant
increase was also observed in the AChE activity in the hypothalamus
of animals treatedwith 50 mg/kg (53%) and 100 mg/kg (40%) of caffeic
acid, while in the cerebellum this increase was observed only in rats
treated with 10 mg/kg (27%) and 50 mg/kg (33%) of caffeic acid
(Pb0.05) (Fig. 5).
Fig. 6 shows the effect of caffeic acid on the AChE activity in lympho-
cytes. This compound signiﬁcantly increased the AChE activity in lym-
phocytes only in animals treated with 100 mg/kg (73%) (Pb0.05). In
relation to the AChE from muscle, it can be observed that caffeic acid
signiﬁcantly increased the enzyme activity in all animals treated with
this compound (10 mg/kg (59%), 50 mg/kg (65%) and 100 mg/kg
(37%)) when compared to the control group (Pb0.05).
In addition, it is also important to note that controls were performed
in vitro and in vivo to correct the vehicle (methanol or canola oil) inter-
ference and no difference between vehicle and control enzymewas ob-
served (Figs. 1–7, groups methanol and oil).
3.2.2. Behavioral tests
Fig. 8 shows the effect of oral administration of caffeic acid (10, 50,
100 mg/kg) once a day during 30 days on test step-down latencies of
rats subjected to the inhibitory avoidance task. Statistical analysis
(Kruskal–Wallis) revealed a signiﬁcant effect of treatment [F(4,35)=
11.54; Pb0.05, Fig. 8]. Post hoc analysis showed that caffeic acid
(100 mg/kg) signiﬁcantly increased step-down latencies compared
to the respective control group, suggesting that oral administration
of caffeic acid improves memory in the inhibitory avoidance task.
Fig. 1. In vitro effects of caffeic acid on theAChE activity in the cerebral cortex, cerebellum, striatum, hippocampus, hypothalamus, andpons of rats. Each bar representsmean±SEM.AChE
activity is expressed as μmol of acetylthiocholine/h/mg of protein. *Different from control (Pb0.05 n=5). ANOVA–Duncan's test.
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training step-down latencies in the inhibitory avoidance task and ex-
ploratory behavior in the open ﬁeld immediately after the inhibitory
avoidance testing session. Statistical analysis (one-way ANOVA) re-
vealed that oral administration of caffeic acid did not alter the training
step-down latencies and the number of crossing or rearing responses
in a subsequent open-ﬁeld testing session (F values shown in Table 1),
suggesting that caffeic acid once a day during 30 days did not cause
gross motor disabilities during testing.
4. Discussion
Caffeic acid, due to its therapeutic properties, represents a promis-
ing candidate for the treatment of many diseases. Although in litera-
ture it is established that caffeic acid has many effects on humanheath, the mechanisms involved in these beneﬁcial properties have
not yet been fully understood. In this study we evaluated in vitro
and in vivo the effects the caffeic acid on the AChE activity in the
brain, whole blood, lymphocytes and muscle of rats as well as the ef-
fect of this compound on memory.
Our results in the brain showed that caffeic acid altered in vitro and
in vivo the AChE activity, but these alterations were not homogeneous
in all evaluated brain structures. In the cerebral cortex, cerebellum
and hypothalamus, caffeic acid signiﬁcantly increased the AChE activity
at concentrations varying from 1.0 to 2.0 mM, while in the striatum,
hippocampus and pons this compounddid not alter the enzyme activity
(Fig. 1). On the other hand, treatment for 30 dayswith caffeic acid at the
dosage of 10 mg/kg, 50 mg/kg and 100 mg/kg inhibited signiﬁcantly
the AChE activity in cerebral cortex and striatum and increased the en-
zyme activity in the hippocampus, hypothalamus and pons (Fig. 5).
Fig. 2. In vitro effect of caffeic acid on the AChE activity in the whole blood of rats. Each
bar represents mean±SEM. AChE activity is expressed as mU/μmol Hb. *Different from
control (Pb0.05 n=5). ANOVA–Duncan's test.
Fig. 4. In vitro effect of caffeic acid on the AChE activity in the muscle of rats. AChE ac-
tivity is expressed as μmol of acetylthiocholine/h/mg of protein. Each bar represents
mean±SEM. *Different from control Pb0.05, ANOVA–Duncan's test.
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tivity in brain regions is the fact that AChE exists in a variety of molec-
ular forms that differ in solubility and type of membrane attachment
rather than in catalytic activity. In the brain, AChE occurs mainly as tet-
rameric G4 forms (membrane bound) together with themonomeric G1
form (cytosolic) (Das et al., 2001). Literature shows thatmanydrugs, in-
cluding those of therapeutic use, did not affect any formof AChE equally
well, most importantly, sometimes these drugs behaved differently,
with the same isoform from different brain areas (Zhao and Tang,
2002). Based on this, we can suggest that caffeic acid also may have
the form speciﬁc selectivity in relation to the AChE from brain regions.
Although this hypothesis must be conﬁrmed with further studies,
these ﬁndings open doors to the discovery of mechanisms about more
speciﬁc targets of the caffeic acid in the CNS.
The AChE activity measured in CNS has been extensively studied not
only because it is involved in the cholinergic neurotransmission (Silman
and Sussman, 2005; Soreq and Seidman, 2001) but also because the del-
eterious consequences of its inhibition (Lotti, 1995) and its action as
therapeutic target in neurodegenerative diseases (Rakonczay, 2003).
AChE is one of the most efﬁcient enzymes known, and its presence
leads to rapid deactivation of acetylcholine at the cholinergic synapse
(Silman and Sussman, 2005). Previous studies have showed that natural
substances and dietary components such as resveratrol (Schmatz et al.,
2009), quercetin (Tota et al., 2010), curcuminoids (Ahmed and Gilani,
2009) and chlorogenic acid (Know et al., 2010) altered the AChE activityFig. 3. In vitro effect of caffeic acid on the AChE activity in lymphocytes of rats. AChE
activity is expressed as μmol of acetylthiocholine/h/mg of protein. Each bar represents
mean±SEM. *Different from control Pb0.05. ANOVA–Duncan's test.in CNS. Although it has been demonstrated that caffeic acid has
neuroprotective effects in many experimental conditions (Yang et al.,
2007; Kalonia et al., 2009; Kart et al., 2009; Sul et al., 2009) our ﬁndings
led us to propose that alterations in the AChE activity induced by caffeic
acid could alter the acetylcholine level interfering in the cholinergic
neurotransmission.
We also observed in this study that animals treated with caffeic acid
only at the dose of 100 mg/kg increased the step-down latencies in rela-
tion to the control group, suggesting that caffeic acid improved the learn-
ing andmemory of rats in the inhibitory avoidance task (Fig. 8), although
the exact mechanism involved in this effect is still unknown. The inhibi-
tory avoidance task is commonly used as a parameter to evaluate the
learning and memory in rats and mice (Izquierdo et al., 2000a,b, 2002).
This task involves the formation of memories through an aversive stim-
ulus (electric shock). Although this aversive stimulus can induce emo-
tional components of fear and anxiety in the animal, this task was
performed in animals treated with caffeic acid in order to evaluate only
the process of learning and memory formation under these conditions.
Some other behavioral parameters to evaluate other types of memory,
such as object recognition, could be used to investigate if the caffeic
acid could improve the memory in other conditions (non-aversive).
These results are important to complement our ﬁndings related to the
caffeic acid effect with the improvement of learning and memory.
Research regarding caffeic acid on behavioral parameters includ-
ing memory tests is scarce in the literature, although some studies
have shown that the acute administration of caffeic acid (1 mg/kg)
increased the number of entries and the time spent in the open
arms of a plus maze suggested an anxiolytic-like effect. The treatment
for 15 days (10 and 30 mg/kg) reverted the alterations in memory
and learning induced by aluminum (Yang et al., 2008) but it remains
unknown if caffeic acid could be interfering in such behavior. Another
important aspect to be discussed is that studies have demonstrated
that caffeic acid phenethyl ester (CAPE), a derivate of caffeic acid, pro-
tects blood brain barrier integrity (Aladag et al., 2006; Zhao et al.,
2012) and has relaxing properties on arteries (Cicala et al., 2003;
Long et al., 2009). Moreover, it has also been reported that caffeic
acid and CAPE are able to ameliorate glucose metabolism and uptake
(Huang et al., 2009; Lee et al., 2007; Tsuda et al., 2012). Taken togeth-
er, the vasodilator effect and the ability to improve the cellular ener-
getic metabolism in the brain can explain, in part, the alterations in
memory observed in the animals treated with caffeic acid with
100 mg/kg.
On the other hand, it is known that AChE inhibitors are used by
improving the memory and other cognitive deﬁcits by increasing
the acetylcholine concentration in the extracellular medium. In this
Fig. 5. In vivo effects of caffeic acid on the AChE activity in the cerebral cortex, cerebellum, hippocampus, hypothalamus, and pons of rats. Each bar represents mean±SEM. AChE
activity is expressed as μmol of acetylthiocholine/h/mg of protein. *Different from control (Pb0.05). ANOVA–Duncan's test.
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in the cortex and striatum. This effect can be important and may be
associated with the improvement of the memory observed. Further-
more, the cholinergic system has synaptic and extra-synaptic functions
(Soreq and Seidman, 2001). Studies have demonstrated that the cholin-
ergic system is involved in brain circulation (Wahl and Schilling, 1993;
Bertrand et al., 1996;Moser et al., 2003). Based on theseﬁndings, caffeic
acid can modulate AChE activity, and depending on the tissue involved
it contributes to the cerebral circulation and improvement of cognitive
performance.
In the present investigation, we also demonstrated that caffeic acid in
vitro and in vivo increased the AChE activity inwhole blood and lympho-
cytes from rats, demonstrating that this compound also affected the cho-
linergic signaling in non neural cells. In blood cells, AChE showed a
similar structure to the enzyme that occurs in neurons, and the catalytic
subunits resemble which was found in synaptic AChE (Thiermann et al.,
2005). AChE is expressed in several types of hematopoietic lineages andcan contribute to cell regulation (Wessler and Kirkpatrick, 2001). Studies
showed that AChE is related to progenitor blood cells mainly for cell
expansion of megakaryocytics and erythrocyte lineages (Soreq and
Seidman, 2001; Soreq et al., 1994; Grisaru et al., 1999). Moreover, the ac-
tivity of this enzyme has been used as an indicator of human cell aging
with lowered levels commonly associated with older human red blood
cells (Prall et al., 1998).
In addition, it has been known that lymphocytes possess a complete
cholinergic system including acetylcholine, choline acetyltransferase,
muscarinic and nicotinic receptors and AChE enzyme (Kawashima and
Fujii, 2000, 2003). Acetylcholine synthesized and released from lym-
phocytes has been considered an immunomodulator acting via both
muscarinic and nicotinic receptors present in these cells (Wessler and
Kirkpatrick, 2001). In this context, AChE emerges as a potential contrib-
utor to the pathway controlling inﬂammatory and immune response in
the blood. In fact, it has been demonstrated that inhibitors of the AChE
reduce lymphocyte proliferation and the secretion of pro-inﬂammatory
Fig. 8. Oral administration of caffeic acid (10, 50 or 100 mg/kg) once a day for 30 days
in the training and test of inhibitory avoidance task. Caffeic acid, 100 mg/kg, improves
memory in inhibitory avoidance test in adult rats. Data are the median±interquartile
range for 8 animals in each group. *Pb0.05 compared with the oil group.Fig. 6. In vivo effect of caffeic acid on the AChE activity in lymphocytes of rats. AChE ac-
tivity is expressed as μmol of acetylthiocholine/h/mg of protein. Each bar represents
mean±SEM. *Different from control Pb0.05. ANOVA–Duncan's test.
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line concentration in the extracellular space (Nizri and Hamra-Amitay,
2006).
Although studies revealed that caffeic acid exhibits radioprotective
effects in human lymphocytes (Devipriya et al., 2008) and that CAPE
has anti-inﬂammatory properties by inhibiting (IL-2) gene transcrip-
tion and IL-2 synthesis in stimulated T cells (Márquez et al., 2004),
our results suggest that the increase in the AChE activity in lymphocytes
by caffeic acid will lead to a decrease in the acetylcholine levels that
could contribute to the onset of low-grade inﬂammation. Theseﬁndings
suggest that caffeic acidmay exert negative effects that demand further
investigations. In this line, other studies described that this compound
has pro-oxidant activity in the presence of transition metal ions such
as iron and copper causing oxidative DNA damage in lymphocytes
(Ahmad et al., 1992; Yamanaka et al., 1997; Galati and Brien, 2004;
Bhat et al., 2007). In addition,Wu et al. (2001) also observed that caffeic
acid exhibits proglycative effects causing elevation of oxidative stress
and inﬂammation inmonocytes, macrophages and vascular endothelial
cells.
AChE is also one of the key functional proteins in neuromuscular
transmission by rapidly hydrolyzing acetylcholine molecules after its
binding to receptors (Gaspersic et al., 1999). It has been demonstrated
that the absence of AChE leads tomarked alterations inmuscle function
including the contractile properties and the lack of resistance to fatigue
(Mouisel et al., 2006; Vignaud et al., 2008). In addition, many diseases
such as myasthenia gravis have been associated with disturbances inFig. 7. In vivo effect of caffeic acid on the AChE activity in the muscle of rats. AChE ac-
tivity is expressed as μmol of acetylthiocholine/h/mg of protein. Each bar represents
mean±SEM. *Different from control Pb0.05, ANOVA–Duncan's test.the acetylcholine homeostasis in the neuromuscular junction and in
some cases inhibitors of AChE are used for the treatment of the symp-
toms (Kokontis and Gutmann, 2000; Shleton, 2002).
In the present study we demonstrated that caffeic acid was capable
of inhibiting in vitro the AChE activity from the muscle at concentra-
tions varying from 0.5 to 2 mM (Fig. 4), while this enzyme activity
was increased when rats were treated with 10, 50 and 100 mg/kg of
caffeic acid for 30 days (Fig. 7). Considering the results obtained in
vivo the increase in the AChE activity caused by the ingestion of caffeic
acid may increase the hydrolysis of acetylcholine at the neuromuscular
junction, decreasing the levels of acetylcholine molecules for interac-
tion with receptors. This activation of AChE by caffeic acid may modify
acetylcholine homeostasis that may trigger cholinergic deﬁcits in neu-
romuscular junction.
Another important aspect is the discrepancy in relation to the results
obtained in vivo and in vitro,mainly in the brain andmuscle (Figs. 1, 4, 5
and 7). The lack of uniformity in the proﬁle of AChE may be a reﬂection
of the route of administration, dose and time of exposure, absorption
and metabolism of caffeic acid in the organism. Taken together, these
associations can contribute to the differences observed between AChE
activity in vivo and in vitro induced by caffeic acid.
Our laboratory has demonstrated that AChE activity is altered in
CNS and lymphocytes in many pathological and experimental condi-
tions (Battisti et al., 2009; Schmatz et al., 2009; Mazzanti et al., 2009;
Kaizer et al., 2009). These ﬁndings reinforce the hypothesis that AChE
may be considered an important therapeutic target in different tis-
sues. In this line, compounds that may interfere with the activity of
this enzyme may be important research targets regarding the treat-
ment of inﬂammatory, cognitive and neurochemical dysfunctions. In
the present study, based on the compiled results we demonstrated
that caffeic acid exerts an effect in the cholinergic system by altering
the AChE activity in different tissues.Table 1
Oral administration of caffeic acid (10,50 or 100 mg/Kg) once a day for 30 days on the
latency of training (inhibitory avoidance task) and behavior of rats (number of crossing
and rearing responses) in the open ﬁeld immediately after the inhibitory avoidance
testing session. Data are means ±SEM for 8 animals in each group.
Group Training Crossing Rearing
Saline 6.37±1.54 23.38±4.32 11.13±2.41
Oil 7.127±0.97 17.38±1.11 7.00±0.96
10 mg/kg 5.37±1.11 18.88±3.30 8.75±1.88
50 mg/kg 15.25±7.06 17.50±3.02 8.87±1.69
100 mg/kg 10.75±2.27 17.88±2.78 11.63±2.87
Statistical analysis F(4,35)=1.377;
P>0.05
F(4,35)=0.662;
P>0.05
F(4,35)=0.835;
P>0.05
Data are means±SEM for 8 animals in each group.
393J. Anwar et al. / Pharmacology, Biochemistry and Behavior 103 (2012) 386–3945. Conclusion
In conclusion, we have shown in this study that caffeic acid in vitro
and in vivo altered the AChE activity in different structures and cells
and improved memory. Further studies are necessary to elucidate the
exact mechanism by which this compound affects the AChE activity
and thus provide important information regarding the use of caffeic
acid as therapeutic option in disorders associated with the cholinergic
system.
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